Benzinga | Jun 15, 2021 09:16AM EDT

Cantor Fitzgerald Initiates Coverage On ADC Therapeutics with Overweight Rating, Announces Price Target of $46

Cantor Fitzgerald analyst Brian Cheng initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Overweight rating and announces Price Target of $46.